Navigation Links
Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
Date:1/21/2009

NEW YORK, Jan. 21, 2009 Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which was partly funded by the Juvenile Diabetes Research Foundation (JDRF), is published in the February 2009 issue of the journal Hypertension.

In the published study, led by Edward P. Feener, Ph.D., an Investigator in the Section on Vascular Cell Biology at the Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School, continuous systemic administration of ASP-440 proved effective in decreasing hypertension-induced increased retinal vascular permeability in rodents, by as much as 70%. Increased retinal vascular permeability is a characteristic finding in diabetic retinopathy and a primary cause of diabetic macular edema, a leading cause of visual impairment associated with diabetes. Hypertension is a known risk factor for the development of retinopathy. ASP-440 was also found to be effective in lowering the elevated blood pressure in these animals.

"These findings represent a pivotal step towards understanding the importance of plasma kallikrein as a target in diabetic eye disease and how its inhibition may support the development of a safe and effective therapy for diabetic retinopathy," said Barbara Araneo, Director of Complications Research for the Juvenile Diabetes Research Foundation. "While further studies are needed to determine the therapeutic potential of ASP-440, the research underscores the relevance of the kallikrein system in diabetic microvascular disease."

In previous JDRF-funded research, Joslin researchers identified plasma kallikrein as a potential therapeutic t
'/>"/>

Contact: Joana Casas
mcasas@jdrf.org
212-479-7560
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers examine developing hearts in chickens to find solutions for human heart abnormalities
2. JDRF-funded researchers discover proteins regulating human beta cell replication
3. Researchers to use K-States BSL-3 Lab for $1 million study of fungus threatening wheat crops
4. Researchers identify potential new weapon in battle against HIV infection
5. U-M researchers discover new genes that fuse in cancer
6. Researchers first to see reactive oxygen species in vital enzyme
7. Dartmouth researchers find new protein function
8. Burnham researchers discover on switch for cell death signaling mechanism
9. Salk researchers develop novel glioblastoma mouse model
10. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
11. The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... down of their woody material, could be the key to ... researchers who add that the approach could also help turn ... major component of woody plant material, is woven in with ... gusts of wind and microbial attack. However, this protective barrier ...
... socioeconomic status and children,s educational environment. Nevertheless, some ... of high parental education and support for learning ... psychologists Angela Friend, John C. DeFries and Richard ... on reading disability, the most commonly identified learning ...
... 22, 2008, Cambridge, UK A new report demonstrates ... hand in seeking out bacteria in chronic infections. ... that can cause severe illness and death. Listeria ... infection is the third most common cause of bacterial ...
Cached Biology News:Modified plants may yield more biofuel 2The effect of parental education on the heritability of children's reading disability 2New research lights up chronic bacterial infection inside bone 2
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... as changes to Martine Rothblatt , Ph.D,s compensation ... United Therapeutics announced the promotion of Roger ... and David Zaccardelli , Pharm.D. to Executive Vice ... promotions, Dr. Rothblatt,s title will change from Chairman and ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)... 15, 2014 METTLER TOLEDO is ... tool, ParticleView V19 with PVM technology , ... particle vision and measurement tool continuously captures high-resolution ... ParticleView V19 then automatically prepares a report pairing ... size and concentration changes. This compelling blend of ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ... proprietary polymer-based oral mucositis product has been launched ... countries by its European commercial partner, SpePharm, a ... of high medical value medicines in supportive and ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, yesterday presented data ... Cancer Research (AACR) in Denver, Colorado, showing that its ... Cancer stem cells are thought to be responsible for ...
... Research and Manufacturers of America (PhRMA) and the national ... to promote three key policies designed to help achieve ... Families USA will work together and will reach out ... incorporated in the healthcare reform proposals to be considered ...
Cached Biology Technology:Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm 2Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm 3Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110 2Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110 3Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110 4PhRMA, Families USA Jointly Promote Measures to Ensure Quality, Affordable Healthcare Coverage 2PhRMA, Families USA Jointly Promote Measures to Ensure Quality, Affordable Healthcare Coverage 3
...
...
... Mouse A-20 cells were cultured in RPMI ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
Biology Products: